Unbiased Analysis of Today's Healthcare Issues
That is the title of my latest column in The Evidence Base. In this latest edition of Perspectives from the Healthcare Economist, Jason Shafrin (FTI Consulting and Mann School of Pharmacy, University of Southern California) examines how AI is beginning to reshape health economics and outcomes research (HEOR), from evidence generation and literature reviews to data analysis…
That is the title of a new paper out yesterday in the Journal of Diabetes Science and Technology from my FTI colleague Marie Steele-Adjognon, along with Martha E. Shepherd, Jon Harris-Shapiro, David Hines, Abraham Lee and Yeesha Poon. The abstract is below. Background: This study evaluated the impact of continuous glucose monitoring (CGM) on health…
That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin (FTI Consulting and Mann School of Pharmacy, University of Southern California) explores a widening divide over how health systems define value, and what that means…
That is the title of a new paper published this week in Clinical Nutrition with co-authors Kyi-Sin Than, Khounish Sharma, Kirk W. Kerr, and Dhanasekhar Kesavelu. The abstract is below: IntroductionPediatric malnutrition is a significant global public health challenge, particularly in low- and middle-income countries. This study quantifies the lifetime, per-person economic impact of pediatric…
That is the title of a paper published today with co-authors Arundati Nagendra (from the Schizophrenia and Psychosis Action Alliance), Raquelle Mesholam-Gately and Matcheri Keshavan (both at the Department of Psychiatry at Harvard Medical School). The abstract is here: Background Schizophrenia is traditionally classified as a serious mental illness (SMI), emphasizing chronicity and disability. However,…
That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse…
I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…
That is the title of a paper I published today in Journal of Market Access & Health Policy with co-authors by Karim EI-Kersh, Nadine Zawadzki, Catelyn Coyle, Shurui Zhang, Dhruv Dalal, Anna Watzker, and Dominik Lautsch. The abstract is below: Pulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses. Due to PAH’s…
That is the topic of an Evidence Base article out today titled “Reflecting on 2025, looking to 2026: Experts outline what to expect for drug pricing and market access“. In the article, a variety of experts reflect on how 2025 reshaped the global drug pricing and market access landscape as well as predict what to…
That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…